Scientists have identified a novel two-pronged treatment method, offering significant potential for patients battling advanced prostate cancer. Experts at The Institute of Cancer Research, London, ...
Hosted on MSN
Prostate cancer breakthrough: life-extending drug will be offered to thousands of men within weeks
Thousands of men with prostate cancer are set to get a life-extending drug on the NHS within weeks – in a breakthrough that could give families precious extra years together. For the first time, ...
Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, talazoparib, which has been approved for NHS use. The once-daily pill, with its ...
The Prostate Cancer Foundation (PCF) today announced the recipients of its 2025 Challenge Awards, providing over $12 million in funding for 12 multi-institutional, cross-disciplinary research teams ...
Morning Overview on MSN
New prostate cancer immunotherapy slashes biomarkers by up to 99%
An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...
A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests. The imaging test highlights aggressive prostate cancer cells, reducing the ...
A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage trial investigated a form of radiotherapy on patients who had stopped ...
LOS ANGELES--(BUSINESS WIRE)--The Prostate Cancer Foundation (PCF) celebrated groundbreaking progress and innovation in the fight against prostate cancer at its 32 nd Annual PCF Scientific Retreat, ...
Add Yahoo as a preferred source to see more of our stories on Google. The once-daily pill, with its brand name Talzenna and produced by Pfizer, offers a crucial at-home treatment option after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results